Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Essen Biotech
Washington University School of Medicine
Astellas Pharma Inc
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
ARCE Therapeutics, Inc.
Fred Hutchinson Cancer Center
Hoffmann-La Roche
Baptist Health South Florida
Arog Pharmaceuticals, Inc.
Columbia University
M.D. Anderson Cancer Center
Washington University School of Medicine
Arog Pharmaceuticals, Inc.
Indiana University
PETHEMA Foundation
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Baylor College of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Baylor College of Medicine
OHSU Knight Cancer Institute
The Korean Society of Pediatric Hematology Oncology